道彤投资

道彤投资

@daltonventure

以生命科学为根，向硬科技生长

111 articles

Articles

Triastek Announces Strategic Collaboration and Equity Investment to Advance the Development of Oral Medicines

Triastek Announces Strategic Collaboration and Equity Investment to Advance the Development of Oral Medicines

On October 9, 2026, **Dalton Venture portfolio company Triastek (Nanjing) Pharmaceutical Technology Co., Ltd.** (hereinafter referred to as "Triastek" or "the Company") announced that **the Company and its wholly-owned subsidiary Triastek (Shanghai) Pharmaceutical Technology Co., Ltd. have entered into a collaboration and license agreement with Johnson & Johnson**. The two parties will combine Johnson & Johnson's expertise in pharmaceutical development with Triastek's

道彤投资·
Dalton Venture Named to Cyzone's 2026 Most Admired VC Firms in Dual Rankings

Dalton Venture Named to Cyzone's 2026 Most Admired VC Firms in Dual Rankings

Recently, Cyzone released its "**Most Admired Venture Capital Firms 2026**" rankings. **Dalton Venture** was selected for the "**Top 50 Most Admired Early-Stage Investment Firms 2026**" and also made the vertical-sector list "**Top 30 Bio/Medical Technology**."

道彤投资·
To See What’s Next for AIVC, Baiyao Technology Partners with MIT Technology Review on Deep Research | Dalton Venture Family

To See What’s Next for AIVC, Baiyao Technology Partners with MIT Technology Review on Deep Research | Dalton Venture Family

On September 21, the report *AI Virtual Cell (AIVC): Technology Trends, Industrial Ecosystem, and Application Prospects — New Infrastructure for Life Sciences in the AI Era* was officially released. Initiated by **Baiyao Technology**, a **Dalton Venture family company**, the report was researched and written by the *MIT Technology Review* China team, and completed under the guidance of the Beijing Zhongguancun Science City Innovation Development. The report takes a global perspective, drawing on research from dozens of scientific institutions worldwide.

道彤投资·
From "Proven Technology" to "Proven Value" | Dalton Venture's Chen Yaochao Invited to 2026 Pujiang Innovation Forum

From "Proven Technology" to "Proven Value" | Dalton Venture's Chen Yaochao Invited to 2026 Pujiang Innovation Forum

On September 13, the **Synthetic Biology Innovation Forum, part of the 2026 Pujiang Innovation Forum, was held in Shanghai, with Yaochao Chen, Managing Director of Dalton Venture and head of its Hong Kong fund, invited to attend.** The forum was hosted by the Ministry of Science and Technology of the People's Republic of China and the Shanghai Municipal People's Government, and organized by the Shanghai Synthetic Biology Innovation Center. It is one of the key thematic forums of the 2026 Pujiang Innovation Forum, bringing together participants from multiple countries including China, the United States, Denmark, Germany, and Switzerland.

道彤投资·
Weibang Zhendian Closes Nearly RMB 100 Million Series B Led by Dalton Venture to Advance Commercialization in Industrial Inspection, Clinical, and AI for Science | Dalton Venture News

Weibang Zhendian Closes Nearly RMB 100 Million Series B Led by Dalton Venture to Advance Commercialization in Industrial Inspection, Clinical, and AI for Science | Dalton Venture News

Recently, **Zhejiang Weibang Zhendian Optoelectronic Technology Co., Ltd. (hereinafter: Weibang Zhendian) completed a nearly RMB 100 million Series B round, led by Dalton Venture with participation from IDG Capital**. The funds will primarily be used to advance the commercialization of its products in industrial inspection, clinical applications, AI for Science, and other fields. Prior to this, Weibang Zhendian had completed two funding rounds, with investors including Tao Capital, FreeS Fund, Founder Hesheng, Naton Capital, and SND Group.

道彤投资·
Dalton Venture Wins Eight Awards from Joy List, Touzijia and Qimingpian for Biotech, AI Medical Breakthroughs, Innovative Devices, Life Sciences, Best Early-Stage Investment Institution and Healthcare Investment Institution

Dalton Venture Wins Eight Awards from Joy List, Touzijia and Qimingpian for Biotech, AI Medical Breakthroughs, Innovative Devices, Life Sciences, Best Early-Stage Investment Institution and Healthcare Investment Institution

Recently, the winners of three major rankings were announced: the 10th Healthcare Investment Excellence Awards, the **Touzijia** 2025–2026 Fund Partner Rankings, and the Qimingpian 2026 Mid-Year China Equity Investment Rankings. Across the three lists, **Ning Huang, founding partner of Dalton Venture, was named to the Best Early-Stage Investor TOP 25, while Dalton Venture was recognized as Best Biotech Investment Firm, Best AI Healthcare Breakthrough Investment Firm, Best Innovative Medical Devices and Life Sciences Investment Firm, and...

道彤投资·
Raybeam Medical Raises Tens of Millions in Angel Round Led by Dalton Venture to Advance Laparoscopic Intraoperative Radiation Therapy Robot

Raybeam Medical Raises Tens of Millions in Angel Round Led by Dalton Venture to Advance Laparoscopic Intraoperative Radiation Therapy Robot

Recently, **Raysure Medical (hereinafter referred to as "Raysure"), an innovative company developing intraoperative radiotherapy robots for endoscopic surgery, announced the completion of a multimillion-yuan angel funding round**. The round was led by Dalton Venture, with participation from Shuimu Tsinghua Alumni Fund, Fortera Capital, and HETANG Venture Capital. The proceeds will be used primarily for animal and clinical trials, product technology iteration, core team expansion, and technology platform development.

道彤投资·